Serum lipoprotein changes following IGF‐I normalization using a growth hormone receptor antagonist in acromegaly

Parkinson, Craig; Drake, William; Wieringa, Gilbert E; Yates, Allen P.; Besser, G. M.; Trainer, Peter J

doi:10.1046/j.1365-2265.2002.01460.x

Cited by 55 publications

(33 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conflicting data exist about the effect of acromegaly on lipid levels. Some studies indicate a worse lipid profile in active acromegaly (9,24) while other authors reported better values (22,25,26) and a worse profile after therapy (26). We found total cholesterol and triglycerides to be significantly lower both in controlled and non-controlled acromegaly.…”

Section: Discussionsupporting

confidence: 51%

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly

Verhelst

Velkeniers²,

Maiter

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Patients with active acromegaly have an increased prevalence of cardiomyopathy and heart failure but a less than expected risk of coronary artery disease, considering the frequent association of diabetes mellitus and hypertension. We examined whether changes in high-sensitive C-reactive protein (hs-CRP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) might contribute to this phenomenon. Design and methods: Two hundred patients of the Belgian acromegaly registry (AcroBel) were divided in two groups: active disease (IGF1 Z-score O2; nZ95) and controlled disease (IGF1 Z-score %2; nZ105). Serum levels of hs-CRP and NT-proBNP were measured and correlated with BMI, blood pressure, fasting lipids, fasting glucose and insulin, HbA1c, IGF1, interleukin 6 (IL6), adiponectin, and sE-selectin. In a subset of acromegaly patients, hs-CRP, IL6, and NT-proBNP levels were also compared with those/the values of an age-, gender-, and BMI-matched reference group.

show abstract

Section: Discussionsupporting

confidence: 51%

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly

Verhelst

Velkeniers²,

Maiter

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Serum total kolesterol düzeylerinin arttığını, normal olduğu-nu ve düştüğünü gösteren çalışmalar vardır [8]. LDL normal olabilmesine rağmen artmış kardiyovaskü-ler mortalite ile ilişkili olan küçük/yoğun LDL, total LDL'nin hakim kısmını oluşturmaktadır [23].…”

Section: Discussionunclassified

“…Buna bağlı olarak hepatik VLDL yapımında artış ve lipoprotein lipaz düzeyinde azalma olabilir. Akromegalide HDL düzeylerinin düştüğü gösterilmiştir [8,9].…”

Section: Introductionunclassified

Evaluation of the metabolic characteristics of patients with Acromegaly

Kılınç

Pekkolay²,

Gözel³

et al. 2016

J Clin Exp Invest

View full text Add to dashboard Cite

Objective: Acromegaly is a syndrome characterized by growth hormone (GH) and insulin like growth factor-1 (IGF-1) over secretion. It was aimed to sharing detected metabolic disorders of the patients with acromegaly who have been under follow-up at our clinic. Methods:One hundred five patients, who were diagnosed as acromegaly in our clinic between 2010 and 2015, were enrolled to the study. The age, gender, involvement feature additional systemic and metabolic diseases were recorded and laboratory findings.Results: A total of 105 patients included in the study, 56 women (53.3%) and 49 men (46.7%), respectively. Patient's' ages ranged 23-78 (mean 42.1±16.7). 34 patients (32.3%), hypertension in 20 (19.04%), diabetes mellitus, and is 11 (10.4%) had impaired glucose tolerance. Conclusion:Somatic disfigurement (hand and foot enlargement etc.) is the major characteristic of the disease but the prognosis is determined by cardiovascular, respiratory and metabolic complications. In acromegaly, hypertension and diabetes are common, cardiovascular disease is the principal cause of death. We believe that our study will contribute to the determination of our country's data. J Clin Exp Invest 2015; 6 (4): 382-386 Key words: Acromegaly, hypertension, diabetes Hipofiz glandında oluşan ve otonom çalışan bir somatotrof adenoma bağlıdır. %95 ön hipofizden aşırı büyüme hormonu salınımına bağlıdır. Hipofiz

show abstract

“…Esse achado poderia representar tanto o efeito direto dos níveis de GH sobre esta proteína quanto o refl exo de possível defi ciência relativa de GH nos pacientes tratados. Em estudo com 20 acromegálicos, avaliados antes e após o pegvisomanto, encontraram-se níveis iniciais reduzidos de colesterol total e LDL, os quais aumentaram após o tratamento (68). Já a Lp-a, inicialmente elevada na maioria dos pacientes, diminuiu com o tratamento.…”

Section: Distúrbios Cardiovasculares Na Acromegaliaunclassified

Distúrbios cardiovasculares na acromegalia

Fedrizzi

Czepielewski

2008

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

A acromegalia acarreta uma série de distúrbios ao sistema cardiovascular, decorrentes da exposição crônica a níveis elevados de GH e IGF-1. Estes distúr-bios são os principais responsáveis pelo aumento da mortalidade de acromegáli-cos. Entre as várias formas de acometimento cardiovascular, destaca-se a miocardiopatia acromegálica, entidade caracterizada, inicialmente, pelo estado hiperdinâmico, seguido de hipertrofi a ventricular esquerda concêntrica e disfunção diastólica por défi cit de relaxamento, culminando com disfunção sistólica e, por vezes, insufi ciência cardíaca franca. Além disso, são também relevantes as arritmias, as valvulopatias, sobretudo mitral e aórtica, a cardiopatia isquêmica, a hipertensão e os distúrbios dos metabolismos glicêmico e lipídico. Nesta revisão são abordados os principais aspectos clínicos e prognósticos destas entidades, os efeitos do tratamento da acromegalia sobre elas e as repercussões correspondentes sobre a sobrevida dos pacientes. ABSTRACT Cardiovascular Disturbances in Acromegaly.Acromegaly causes a number of disorders in the cardiovascular system, resulting from chronic exposure to high levels of GH and IGF-1. Such disorders are the main responsible for increased mortality rates among acromegalic patients. Among several forms of cardiovascular impairment is acromegalic cardiomyopathy, an entity that is initially characterized by a hyperdynamic state, followed by concentric left ventricular hypertrophy and diastolic dysfunction due to relaxation defi cit, culminating in systolic dysfunction and sometimes heart failure. In addition, arrhythmias and heart valve diseases are also relevant, especially mitral and aortic, ischemic heart disease, hypertension, and glucose and lipid metabolism disorders. This review approaches the main clinical and prognostic aspects of these entities, the effects of acromegaly treatment on them, and the respective consequences on patient survival. (Arq Bras Endocrinol Metab 2008; 52/9:1416-1429)

show abstract

Serum lipoprotein changes following IGF‐I normalization using a growth hormone receptor antagonist in acromegaly

Cited by 55 publications

References 74 publications

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels: insights from the Belgian registry of acromegaly

Evaluation of the metabolic characteristics of patients with Acromegaly

Distúrbios cardiovasculares na acromegalia

Contact Info

Product

Resources

About